Molecular targets of botulinum toxin at the mammalian neuromuscular junction

被引:24
|
作者
Whelchel, DD [1 ]
Breluner, TM [1 ]
Brooks, PM [1 ]
Coffield, JA [1 ]
机构
[1] Univ Georgia, Coll Vet Med, Dept Physiol & Pharmacol, Athens, GA 30602 USA
关键词
Botulinum neurotoxin; neuromuscular junction; paralysis; SNAP-25; VAMP; sprouting;
D O I
10.1002/mds.20004
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The molecular targets of botulinum neurotoxins (BoNTs) are SNARE (soluble N-ethylmaleimide-sensitive factor-attachment protein-receptor) proteins necessary for neurotransmitter release. BoNT are powerful therapeutic agents in the treatment of numerous neurological disorders. The goals of this study were to (1) assess toxin diffusion by measuring substrate cleavage in adjacent and distant muscles, and (2) characterize the clinical course using SNARE protein chemistry. A small volume of BoNT/A was injected unilaterally into the mouse gastrocnernius muscle. Motor impairment was limited to the toxin-treated limb. No systemic illness or deaths occurred. At five time points, a subset of mice were killed, and muscles from both hindlimbs, and the diaphragm, were collected. Protein samples were examined for changes in SNAP-25 (synaptosomal-associated protein of Mr = 25 kDa) using immunochemistry. SNAP-25 cleavage product was noted in the toxin-treated limb as early as 1 day postinjection and continued through day 28. Onset and peak levels of substrate cleavage corresponded to the onset and peak clinical response. Cleavage was observed in adjacent and distant muscles, demonstrating that substrate cleavage is a sensitive indicator of toxin diffusion. Significant increases in full-length SNAP-25 and vesicle-associated membrane protein II were evident early in the impaired limb and continued through day 28. The increased SNARE protein most likely originates from nerve terminal sprouts. (C) 2004 Movement Disorder Society.
引用
收藏
页码:S7 / S16
页数:10
相关论文
共 50 条
  • [21] Modulating Neuromuscular Junction Density Changes in Botulinum Toxin-Treated Orbicularis Oculi Muscle
    Harrison, Andrew R.
    Berbos, Zachary
    Zaldivar, Renzo A.
    Anderson, Brian C.
    Semmer, Mollie
    Lee, Michael S.
    McLoon, Linda K.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2011, 52 (02) : 982 - 986
  • [22] BOTULINUM TOXIN BLOCKS QUANTAL BUT NOT NON-QUANTAL RELEASE OF ACH AT THE NEUROMUSCULAR-JUNCTION
    STANLEY, EF
    DRACHMAN, DB
    BRAIN RESEARCH, 1983, 261 (01) : 172 - 175
  • [23] Molecular Mechanisms of Treadmill Therapy on Neuromuscular Atrophy Induced via Botulinum Toxin A
    Tsai, Sen-Wei
    Chen, Hsiao-Ling
    Chang, Yi-Chun
    Chen, Chuan-Mu
    NEURAL PLASTICITY, 2013, 2013
  • [25] Structure and Function of the Mammalian Neuromuscular Junction
    Davis, Leah A.
    Fogarty, Matthew J.
    Brown, Alyssa
    Sieck, Gary C.
    COMPREHENSIVE PHYSIOLOGY, 2022, 12 (04) : 3731 - 3766
  • [26] Comparative anatomy of the mammalian neuromuscular junction
    Boehm, Ines
    Alhindi, Abrar
    Leite, Ana S.
    Logie, Chandra
    Gibbs, Alyssa
    Murray, Olivia
    Farrukh, Rizwan
    Pirie, Robert
    Proudfoot, Christopher
    Clutton, Richard
    Wishart, Thomas M.
    Jones, Ross A.
    Gillingwater, Thomas H.
    JOURNAL OF ANATOMY, 2020, 237 (05) : 827 - 836
  • [27] VERATRUM ALKALOIDS ON MAMMALIAN NEUROMUSCULAR JUNCTION
    OKAMOTO, M
    BAKER, T
    FEDERATION PROCEEDINGS, 1969, 28 (02) : 669 - &
  • [28] THE ULTRASTRUCTURE OF THE MAMMALIAN NEUROMUSCULAR JUNCTION (NMJ)
    LEHRER, GM
    ORNSTEIN, L
    ANATOMICAL RECORD, 1959, 133 (02): : 303 - 303
  • [29] Localization of Dlg at the mammalian neuromuscular junction
    Rafael, JA
    Hutchinson, TL
    Lumeng, CN
    Marfatia, SM
    Chishti, AH
    Chamberlain, JS
    NEUROREPORT, 1998, 9 (09) : 2121 - 2125
  • [30] TOXICITY OF BOTULINUM TOXIN - STOICHIOMETRIC MODEL FOR THE LOCUS OF ITS EXTRAORDINARY POTENCY AND PERSISTENCE AT THE NEUROMUSCULAR-JUNCTION
    HANIG, JP
    LAMANNA, C
    JOURNAL OF THEORETICAL BIOLOGY, 1979, 77 (01) : 107 - 113